Business
Rallybio Reports First Quarter 2023 Financial Results
-- RLYB212 Phase 1b Proof-of-Concept Study Results to be Presented at 31st Congress of the International Society of Thrombosis and Haemostasis (ISTH) in June
About this update from Rallybio Corporation
[{"type":"text","content":"\n-- RLYB212 Phase 1b Proof-of-Concept Study Results to be Presented at 31st Congress of the International Society of Thrombosis and Haemostasis (ISTH) in June 2023 --\n\n\n-- Phase 1 Multiple Dose Cohort RLYB212 Study Initiated in 1Q 2023; Data Expected in 4Q 2023 --\n\n\n-- Phase 1 Multiple Ascending Dose Study of RLYB116 Continues to Progress; Safety, PK and PD Data Expected in 4Q 2023 --\n\n\n-- $150.4 million cash, cash equivalents and marketable securities as of March 31, 2023; Provides Runway into 1Q 2025 --\n\n\n NEW HAVEN, Conn.--(BUSINESS WIRE)--\nRallybio Corporation (Nasdaq: RLYB) today reported financial results for the first quarter ended March 31, 2023 and provided an update on recent program and corporate developments.\n\n\n“We continue to progress our pipeline toward planned upcoming milestones. We recently announced that the Phase 1b proof-of-concept study results for RLYB212, our anti-HPA-1a monoclonal antibody product candidate for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT), will be presented at the International Society on Thrombosis and Haemostasis Congress. While physicians have high awareness of the catastrophic impact of FNAIT and a desire to proactively treat expectant at-risk mothers, there are currently no approved therapies available to the thousands of women impacted each year. We look forward to sharing our Phase 1b data in June, as we continue to educate healthcare providers and their patients on the potential opportunity for RLYB212. We also continue to enroll the multiple dose cohort of our ongoing Phase 1 trial, and expect to report results from this cohort in the fourth quarter of 2023. Later this year, we expect to provide additional details regarding our clinical development plans for RLYB212,” said Martin Mackay, Ph.D., Chief Executive Officer of Rallybio.\n\n\nDr. Mackay continued, “We continue to advance efforts across our programs in complement dysregulation, hematology and metabolic disorders. Our multiple ascending dose Phase 1 study of RLYB116, an inhibitor of complement component 5 (C5), also continues to progress and we expect to share initial data from this study, as well as details on our initial indication strategy, in the fourth quarter of 2023. As we continue our development of potentially transformative medicines for underserved rare diseases, we ...